GlaxoSmithKline: Executive Compensation and a Shareholder Revolt

  • Supplementary Resources


A series of controversies and market reversals begin to affect one of the world’s largest pharmaceutical firms. As share price tumbles and market share erodes, CEO J.P. Garnier is awarded a very large compensation package early in 2003. Shareholders revolt, voting down the executive compensation package, and threaten to take down the management team. GSK Chairman Lord Christopher Hogg and Communications VP Jennie Younger must decide how to proceed in the face of mounting criticism and public outrage.

You are not authorized to view Teaching Notes. Please contact your librarian for access or sign in to your existing instructor profile.
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles